VALNEVA SE (VLA.PA) Stock Price & Overview
EPA:VLA • FR0004056851
Current stock price
The current stock price of VLA.PA is 4.544 EUR. Today VLA.PA is up by 0.8%. In the past month the price increased by 4.75%. In the past year, price increased by 44.25%.
VLA.PA Key Statistics
- Market Cap
- 394M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -0.64
- Dividend Yield
- N/A
VLA.PA Stock Performance
VLA.PA Stock Chart
VLA.PA Technical Analysis
ChartMill assigns a technical rating of 8 / 10 to VLA.PA. When comparing the yearly performance of all stocks, VLA.PA is one of the better performing stocks in the market, outperforming 91.49% of all stocks.
VLA.PA Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to VLA.PA. VLA.PA has a bad profitability rating. Also its financial health evaluation is rather negative.
VLA.PA Earnings
On November 20, 2025 VLA.PA reported an EPS of -0.26 and a revenue of 29.44M. The company missed EPS expectations (-90.69% surprise) and missed revenue expectations (-26.86% surprise).
VLA.PA Forecast & Estimates
11 analysts have analysed VLA.PA and the average price target is 7.37 EUR. This implies a price increase of 62.1% is expected in the next year compared to the current price of 4.544.
For the next year, analysts expect an EPS growth of -619.02% and a revenue growth -7.65% for VLA.PA
VLA.PA Groups
Sector & Classification
VLA.PA Financial Highlights
Over the last trailing twelve months VLA.PA reported a non-GAAP Earnings per Share(EPS) of -0.64. The EPS decreased by -1180% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -26.86% | ||
| ROE | -80.02% | ||
| Debt/Equity | 0.89 |
VLA.PA Ownership
VLA.PA Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ARGX | ARGENX SE | 25.25 | 37.984B | ||
| 1AE | ARGENX SE | 25.18 | 37.885B | ||
| 22UA | BIONTECH SE-ADR | N/A | 18.924B | ||
| 2X1 | ABIVAX SA | N/A | 8.018B | ||
| ABVX | ABIVAX SA | N/A | 8.002B | ||
| GXE | GALAPAGOS NV | N/A | 1.824B | ||
| GLPG | GALAPAGOS NV | N/A | 1.82B | ||
| NANO | NANOBIOTIX | N/A | 1.396B | ||
| 6IV | INVENTIVA SA | N/A | 1.087B | ||
| IVA | INVENTIVA SA | N/A | 1.067B | ||
| PHIL | PHILOGEN SPA | 18.09 | 660.824M | ||
| XUP | GENFIT | 917.65 | 468.027M | ||
| GNFT | GENFIT | 832.35 | 424.525M |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Euronext Paris Exchange | Find stocks with similar TA and Setup ratings on the EuroNext exchanges | Find stocks with similar Fundamental rating on the EuroNext exchanges | Find the competitors with the best technical ratings on the EuroNext exchanges | Find the competitors with the best fundamentals on the EuroNext exchanges | Find the competitors with the best valuation on the EuroNext exchanges | Find the competitors with the best dividend on the EuroNext exchanges | Find the competitors with the best analyst ratings on the EuroNext exchanges
About VLA.PA
Company Profile
Valneva SE is a specialty vaccine company that develops, manufactures, and commercializes prophylactic vaccines for infectious diseases addressing unmet medical needs. The company is headquartered in Saint-Herblain, Pays De La Loire and currently employs 695 full-time employees. The company went IPO on 2007-06-28. The firm's portfolio includes two commercial vaccines for travelers: IXIARO/JESPECT, for the prevention of Japanese Encephalitis, and DUKORAL, which is indicated for the prevention of cholera and, in some countries, prevention of diarrhea caused by Enterotoxigenic escherichia coli (ETEC). The firm has also vaccines in development, including candidates against Lyme disease, COVID-19 and chikungunya. Its technologies and services segment cooperates with various pharmaceutical companies using its platform: EB66 vaccine production cell line and IC31 adjuvant. The firm is focused on research and development (R&D) programs, as well as holds investment in product candidates and commercial products.
Company Info
IPO: 2007-06-28
VALNEVA SE
6, Rue Alain Bombard
Saint-Herblain PAYS DE LA LOIRE FR
Employees: 713
Phone: 33228073710
VALNEVA SE / VLA.PA FAQ
Can you describe the business of VALNEVA SE?
Valneva SE is a specialty vaccine company that develops, manufactures, and commercializes prophylactic vaccines for infectious diseases addressing unmet medical needs. The company is headquartered in Saint-Herblain, Pays De La Loire and currently employs 695 full-time employees. The company went IPO on 2007-06-28. The firm's portfolio includes two commercial vaccines for travelers: IXIARO/JESPECT, for the prevention of Japanese Encephalitis, and DUKORAL, which is indicated for the prevention of cholera and, in some countries, prevention of diarrhea caused by Enterotoxigenic escherichia coli (ETEC). The firm has also vaccines in development, including candidates against Lyme disease, COVID-19 and chikungunya. Its technologies and services segment cooperates with various pharmaceutical companies using its platform: EB66 vaccine production cell line and IC31 adjuvant. The firm is focused on research and development (R&D) programs, as well as holds investment in product candidates and commercial products.
Can you provide the latest stock price for VALNEVA SE?
The current stock price of VLA.PA is 4.544 EUR. The price increased by 0.8% in the last trading session.
What is the dividend status of VALNEVA SE?
VLA.PA does not pay a dividend.
What is the ChartMill rating of VALNEVA SE stock?
VLA.PA has a ChartMill Technical rating of 8 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
On which exchange is VLA.PA stock listed?
VLA.PA stock is listed on the Euronext Paris exchange.
Can you provide the number of employees for VALNEVA SE?
VALNEVA SE (VLA.PA) currently has 713 employees.
Who owns VALNEVA SE?
You can find the ownership structure of VALNEVA SE (VLA.PA) on the Ownership tab.